E-Mail
IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more
Credit: City of Hope
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in
E-Mail
(Singapore 4:45 p.m. SPT/3:45 a.m. EST January 30, 2021 Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented today at the International Association for the Study of Lung Cancer s 2020 World Conference on Lung Cancer Singapore.
Immune checkpoint inhibitors have revolutionized cancer care in patients with advanced stage aNSCLC, but better predictors of treatment response are still needed to guide treatment decisions for patients diagnosed with NSCLC, according to Dr. Wallace Akerley, of Huntsman Cancer Institute in Salt Lake City, Utah. HIC (Host Immune Classifier) is a serum proteomic measure of inflammation. Hot implies that the tumor is inflamed.
He was diagnosed with prostate cancer 8 years ago and now he’s on a mission to help find a cure
elisfkc2 / Flickr / CC BY-SA 2.0
POCATELLO, Idaho (East Idaho News) During a routine checkup in 2008, Zach Parris’s doctor suggested he get a Prostate Specific Antigen test. It’s a blood test that determines whether you have prostate cancer.
Cancer had never been an issue for the 49-year-old Pocatello resident or anyone in his family and he had always been healthy, so he was a little surprised at his doctor’s recommendation. Men 50 and older have an increased chance of getting prostate cancer and his doctor felt getting tested would be a good idea.
Have hospital-at-home programs finally come of age?
Bill Eggbeer
Hospital-at-home programs have existed for more than 20 years. But only recently have they started to build momentum.
The COVID-19 pandemic has significantly accelerated interest in developing and expanding hospital-at-home programs, and with new payment support from CMS, these programs can be expected to proliferate in coming months and years. For those health systems with their own health plans and/or with a significant enrollment in accountable care organizations (ACOs) that are taking significant financial risk, a hospital-at-home program can offer the potential to improve care and reduce costs for a segment of the patient population.